Home   Search   Browse   Statistics   User guide   FAQs   Post question   Download   Process data  
Search results for the GEO ID: GSE38680
(Click on the check boxes provided under "Select for analysis", to initiate grouping)
(Once the selection is made, click on "Add groups" in "Make groups for comparison", to make a group. Scroll down)
GSM ID
GPL ID
Select for analysis
Title
Source name
Description
Characteristics
GSM947461
GPL570
Biceps_Control_1 Biceps muscle, Control patient tissue: Biceps muscle patient: C.b.1 diagnosis: Control treatment: None treatment time (rhgaa): -- gender: M age at baseline: 1y 2m motor status (52 weeks treatment): -- change in glycogen content (52 weeks treatment): -- response: --
GSM947462
GPL570
Biceps_Control_2 Biceps muscle, Control patient tissue: Biceps muscle patient: C.b.2 diagnosis: Control treatment: None treatment time (rhgaa): -- gender: M age at baseline: 1y 11m motor status (52 weeks treatment): -- change in glycogen content (52 weeks treatment): -- response: --
GSM947463
GPL570
Biceps_Control_3 Biceps muscle, Control patient tissue: Biceps muscle patient: C.b.3 diagnosis: Control treatment: None treatment time (rhgaa): -- gender: M age at baseline: 2y 1m motor status (52 weeks treatment): -- change in glycogen content (52 weeks treatment): -- response: --
GSM947464
GPL570
Biceps_Control_4 Biceps muscle, Control patient tissue: Biceps muscle patient: C.b.4 diagnosis: Control treatment: None treatment time (rhgaa): -- gender: M age at baseline: 2m motor status (52 weeks treatment): -- change in glycogen content (52 weeks treatment): -- response: --
GSM947465
GPL570
Biceps_Control_5 Biceps muscle, Control patient tissue: Biceps muscle patient: C.b.5 diagnosis: Control treatment: None treatment time (rhgaa): -- gender: F age at baseline: 2y motor status (52 weeks treatment): -- change in glycogen content (52 weeks treatment): -- response: --
GSM947466
GPL570
Biceps_Control_6 Biceps muscle, Control patient tissue: Biceps muscle patient: C.b.6 diagnosis: Control treatment: None treatment time (rhgaa): -- gender: F age at baseline: 2y motor status (52 weeks treatment): -- change in glycogen content (52 weeks treatment): -- response: --
GSM947467
GPL570
Biceps_Control_7 Biceps muscle, Control patient tissue: Biceps muscle patient: C.b.7 diagnosis: Control treatment: None treatment time (rhgaa): -- gender: F age at baseline: 2y 3m motor status (52 weeks treatment): -- change in glycogen content (52 weeks treatment): -- response: --
GSM947468
GPL570
Biceps_Control_8 Biceps muscle, Control patient tissue: Biceps muscle patient: C.b.8 diagnosis: Control treatment: None treatment time (rhgaa): -- gender: F age at baseline: 1y 9m motor status (52 weeks treatment): -- change in glycogen content (52 weeks treatment): -- response: --
GSM947469
GPL570
Biceps_Control_9 Biceps muscle, Control patient tissue: Biceps muscle patient: C.b.9 diagnosis: Control treatment: None treatment time (rhgaa): -- gender: F age at baseline: 2y 11m motor status (52 weeks treatment): -- change in glycogen content (52 weeks treatment): -- response: --
GSM947470
GPL570
Biceps_Control_10 Biceps muscle, Control patient tissue: Biceps muscle patient: C.b.10.MELAS diagnosis: Control treatment: None treatment time (rhgaa): -- gender: M age at baseline: 2y 9m motor status (52 weeks treatment): -- change in glycogen content (52 weeks treatment): -- response: --
GSM947471
GPL570
Biceps_Pompe_1 Biceps muscle, Pompe patient tissue: Biceps muscle patient: P.b.1 diagnosis: Pompe treatment: None treatment time (rhgaa): -- gender: M age at baseline: 7m motor status (52 weeks treatment): -- change in glycogen content (52 weeks treatment): -- response: --
GSM947472
GPL570
Biceps_Pompe_2 Biceps muscle, Pompe patient tissue: Biceps muscle patient: P.b.2 diagnosis: Pompe treatment: None treatment time (rhgaa): -- gender: M age at baseline: 4m motor status (52 weeks treatment): -- change in glycogen content (52 weeks treatment): -- response: --
GSM947473
GPL570
Biceps_Pompe_3 Biceps muscle, Pompe patient tissue: Biceps muscle patient: P.b.3 diagnosis: Pompe treatment: None treatment time (rhgaa): -- gender: M age at baseline: 7m motor status (52 weeks treatment): -- change in glycogen content (52 weeks treatment): -- response: --
GSM947474
GPL570
Biceps_Pompe_4 Biceps muscle, Pompe patient tissue: Biceps muscle patient: P.b.4 diagnosis: Pompe treatment: None treatment time (rhgaa): -- gender: M age at baseline: 10m motor status (52 weeks treatment): -- change in glycogen content (52 weeks treatment): -- response: --
GSM947475
GPL570
Biceps_Pompe_5 Biceps muscle, Pompe patient tissue: Biceps muscle patient: P.b.5 diagnosis: Pompe treatment: None treatment time (rhgaa): -- gender: M age at baseline: 4m motor status (52 weeks treatment): -- change in glycogen content (52 weeks treatment): -- response: --
GSM947476
GPL570
Biceps_Pompe_6 Biceps muscle, Pompe patient tissue: Biceps muscle patient: P.b.6 diagnosis: Pompe treatment: None treatment time (rhgaa): -- gender: F age at baseline: 4m motor status (52 weeks treatment): -- change in glycogen content (52 weeks treatment): -- response: --
GSM947477
GPL570
Biceps_Pompe_7 Biceps muscle, Pompe patient tissue: Biceps muscle patient: P.b.7 diagnosis: Pompe treatment: None treatment time (rhgaa): -- gender: F age at baseline: 7m motor status (52 weeks treatment): -- change in glycogen content (52 weeks treatment): -- response: --
GSM947478
GPL570
Biceps_Pompe_8 Biceps muscle, Pompe patient tissue: Biceps muscle patient: P.b.8 diagnosis: Pompe treatment: None treatment time (rhgaa): -- gender: F age at baseline: 1y 5m motor status (52 weeks treatment): -- change in glycogen content (52 weeks treatment): -- response: --
GSM947479
GPL570
Biceps_Pompe_9 Biceps muscle, Pompe patient tissue: Biceps muscle patient: P.b.9 diagnosis: Pompe treatment: None treatment time (rhgaa): -- gender: F age at baseline: 1m motor status (52 weeks treatment): -- change in glycogen content (52 weeks treatment): -- response: --
GSM947480
GPL570
Quadriceps_Control_1 Quadriceps muscle, Control patient tissue: Quadriceps muscle patient: C.q.1 diagnosis: Control treatment: None treatment time (rhgaa): -- gender: M age at baseline: 5y motor status (52 weeks treatment): -- change in glycogen content (52 weeks treatment): -- response: --
GSM947481
GPL570
Quadriceps_Control_2 Quadriceps muscle, Control patient tissue: Quadriceps muscle patient: C.q.2 diagnosis: Control treatment: None treatment time (rhgaa): -- gender: M age at baseline: 6m motor status (52 weeks treatment): -- change in glycogen content (52 weeks treatment): -- response: --
GSM947482
GPL570
Quadriceps_Control_3 Quadriceps muscle, Control patient tissue: Quadriceps muscle patient: C.q.3 diagnosis: Control treatment: None treatment time (rhgaa): -- gender: M age at baseline: 9y motor status (52 weeks treatment): -- change in glycogen content (52 weeks treatment): -- response: --
GSM947483
GPL570
Quadriceps_Control_4 Quadriceps muscle, Control patient tissue: Quadriceps muscle patient: C.q.4 diagnosis: Control treatment: None treatment time (rhgaa): -- gender: F age at baseline: 8m motor status (52 weeks treatment): -- change in glycogen content (52 weeks treatment): -- response: --
GSM947484
GPL570
Quadriceps_Control_5 Quadriceps muscle, Control patient tissue: Quadriceps muscle patient: C.q.5 diagnosis: Control treatment: None treatment time (rhgaa): -- gender: F age at baseline: 6m motor status (52 weeks treatment): -- change in glycogen content (52 weeks treatment): -- response: --
GSM947485
GPL570
Quadriceps_Control_6 Quadriceps muscle, Control patient tissue: Quadriceps muscle patient: C.q.6 diagnosis: Control treatment: None treatment time (rhgaa): -- gender: M age at baseline: 5m motor status (52 weeks treatment): -- change in glycogen content (52 weeks treatment): -- response: --
GSM947486
GPL570
Quadriceps_Control_7 Quadriceps muscle, Control patient tissue: Quadriceps muscle patient: C.q.7 diagnosis: Control treatment: None treatment time (rhgaa): -- gender: F age at baseline: 6m motor status (52 weeks treatment): -- change in glycogen content (52 weeks treatment): -- response: --
GSM947487
GPL570
Quadriceps_Pompe_1_00wks Quadriceps muscle, Pompe patient, 0 weeks rhGAA treatment tissue: Quadriceps muscle patient: P.q.1 diagnosis: Pompe treatment: rhGAA treatment time (rhgaa): 00 Weeks gender: M age at baseline: 5m motor status (52 weeks treatment): No gains change in glycogen content (52 weeks treatment): Increased response: Poor Clinical Outcome
GSM947488
GPL570
Quadriceps_Pompe_1_12wks Quadriceps muscle, Pompe patient, 12 weeks rhGAA treatment tissue: Quadriceps muscle patient: P.q.1 diagnosis: Pompe treatment: rhGAA treatment time (rhgaa): 12 Weeks gender: M age at baseline: 5m motor status (52 weeks treatment): No gains change in glycogen content (52 weeks treatment): Increased response: Poor Clinical Outcome
GSM947489
GPL570
Quadriceps_Pompe_1_52wks Quadriceps muscle, Pompe patient, 52 weeks rhGAA treatment tissue: Quadriceps muscle patient: P.q.1 diagnosis: Pompe treatment: rhGAA treatment time (rhgaa): 52 Weeks gender: M age at baseline: 5m motor status (52 weeks treatment): No gains change in glycogen content (52 weeks treatment): Increased response: Poor Clinical Outcome
GSM947490
GPL570
Quadriceps_Pompe_2_00wks Quadriceps muscle, Pompe patient, 0 weeks rhGAA treatment tissue: Quadriceps muscle patient: P.q.2 diagnosis: Pompe treatment: rhGAA treatment time (rhgaa): 00 Weeks gender: M age at baseline: 7m motor status (52 weeks treatment): Walking change in glycogen content (52 weeks treatment): Stable response: Positive Clinical Outcome
GSM947491
GPL570
Quadriceps_Pompe_2_12wks Quadriceps muscle, Pompe patient, 12 weeks rhGAA treatment tissue: Quadriceps muscle patient: P.q.2 diagnosis: Pompe treatment: rhGAA treatment time (rhgaa): 12 Weeks gender: M age at baseline: 7m motor status (52 weeks treatment): Walking change in glycogen content (52 weeks treatment): Stable response: Positive Clinical Outcome
GSM947492
GPL570
Quadriceps_Pompe_2_52wks Quadriceps muscle, Pompe patient, 52 weeks rhGAA treatment tissue: Quadriceps muscle patient: P.q.2 diagnosis: Pompe treatment: rhGAA treatment time (rhgaa): 52 Weeks gender: M age at baseline: 7m motor status (52 weeks treatment): Walking change in glycogen content (52 weeks treatment): Stable response: Positive Clinical Outcome
GSM947493
GPL570
Quadriceps_Pompe_3_00wks Quadriceps muscle, Pompe patient, 0 weeks rhGAA treatment tissue: Quadriceps muscle patient: P.q.3 diagnosis: Pompe treatment: rhGAA treatment time (rhgaa): 00 Weeks gender: F age at baseline: 5.7m motor status (52 weeks treatment): No gains change in glycogen content (52 weeks treatment): Decreased response: Poor Clinical Outcome
GSM947494
GPL570
Quadriceps_Pompe_3_12wks Quadriceps muscle, Pompe patient, 12 weeks rhGAA treatment tissue: Quadriceps muscle patient: P.q.3 diagnosis: Pompe treatment: rhGAA treatment time (rhgaa): 12 Weeks gender: F age at baseline: 5.7m motor status (52 weeks treatment): No gains change in glycogen content (52 weeks treatment): Decreased response: Poor Clinical Outcome
GSM947495
GPL570
Quadriceps_Pompe_3_52wks Quadriceps muscle, Pompe patient, 52 weeks rhGAA treatment tissue: Quadriceps muscle patient: P.q.3 diagnosis: Pompe treatment: rhGAA treatment time (rhgaa): 52 Weeks gender: F age at baseline: 5.7m motor status (52 weeks treatment): No gains change in glycogen content (52 weeks treatment): Decreased response: Poor Clinical Outcome
GSM947496
GPL570
Quadriceps_Pompe_4_00wks Quadriceps muscle, Pompe patient, 0 weeks rhGAA treatment tissue: Quadriceps muscle patient: P.q.4 diagnosis: Pompe treatment: rhGAA treatment time (rhgaa): 00 Weeks gender: M age at baseline: 5.9m motor status (52 weeks treatment): No gains change in glycogen content (52 weeks treatment): Increased response: Poor Clinical Outcome
GSM947497
GPL570
Quadriceps_Pompe_4_12wks Quadriceps muscle, Pompe patient, 12 weeks rhGAA treatment tissue: Quadriceps muscle patient: P.q.4 diagnosis: Pompe treatment: rhGAA treatment time (rhgaa): 12 Weeks gender: M age at baseline: 5.9m motor status (52 weeks treatment): No gains change in glycogen content (52 weeks treatment): Increased response: Poor Clinical Outcome
GSM947498
GPL570
Quadriceps_Pompe_4_52wks Quadriceps muscle, Pompe patient, 52 weeks rhGAA treatment tissue: Quadriceps muscle patient: P.q.4 diagnosis: Pompe treatment: rhGAA treatment time (rhgaa): 52 Weeks gender: M age at baseline: 5.9m motor status (52 weeks treatment): No gains change in glycogen content (52 weeks treatment): Increased response: Poor Clinical Outcome
GSM947499
GPL570
Quadriceps_Pompe_5_00wks Quadriceps muscle, Pompe patient, 0 weeks rhGAA treatment tissue: Quadriceps muscle patient: P.q.5 diagnosis: Pompe treatment: rhGAA treatment time (rhgaa): 00 Weeks gender: M age at baseline: 6.9m motor status (52 weeks treatment): Walking change in glycogen content (52 weeks treatment): Decreased response: Positive Clinical Outcome
GSM947500
GPL570
Quadriceps_Pompe_5_12wks Quadriceps muscle, Pompe patient, 12 weeks rhGAA treatment tissue: Quadriceps muscle patient: P.q.5 diagnosis: Pompe treatment: rhGAA treatment time (rhgaa): 12 Weeks gender: M age at baseline: 6.9m motor status (52 weeks treatment): Walking change in glycogen content (52 weeks treatment): Decreased response: Positive Clinical Outcome
GSM947501
GPL570
Quadriceps_Pompe_5_52wks Quadriceps muscle, Pompe patient, 52 weeks rhGAA treatment tissue: Quadriceps muscle patient: P.q.5 diagnosis: Pompe treatment: rhGAA treatment time (rhgaa): 52 Weeks gender: M age at baseline: 6.9m motor status (52 weeks treatment): Walking change in glycogen content (52 weeks treatment): Decreased response: Positive Clinical Outcome
GSM947502
GPL570
Quadriceps_Pompe_6_00wks Quadriceps muscle, Pompe patient, 0 weeks rhGAA treatment tissue: Quadriceps muscle patient: P.q.6 diagnosis: Pompe treatment: rhGAA treatment time (rhgaa): 00 Weeks gender: M age at baseline: 4.3m motor status (52 weeks treatment): Walking change in glycogen content (52 weeks treatment): Decreased response: Positive Clinical Outcome
GSM947503
GPL570
Quadriceps_Pompe_6_12wks Quadriceps muscle, Pompe patient, 12 weeks rhGAA treatment tissue: Quadriceps muscle patient: P.q.6 diagnosis: Pompe treatment: rhGAA treatment time (rhgaa): 12 Weeks gender: M age at baseline: 4.3m motor status (52 weeks treatment): Walking change in glycogen content (52 weeks treatment): Decreased response: Positive Clinical Outcome
GSM947504
GPL570
Quadriceps_Pompe_6_52wks Quadriceps muscle, Pompe patient, 52 weeks rhGAA treatment tissue: Quadriceps muscle patient: P.q.6 diagnosis: Pompe treatment: rhGAA treatment time (rhgaa): 52 Weeks gender: M age at baseline: 4.3m motor status (52 weeks treatment): Walking change in glycogen content (52 weeks treatment): Decreased response: Positive Clinical Outcome
GSM947505
GPL570
Quadriceps_Pompe_7_00wks Quadriceps muscle, Pompe patient, 0 weeks rhGAA treatment tissue: Quadriceps muscle patient: P.q.7 diagnosis: Pompe treatment: rhGAA treatment time (rhgaa): 00 Weeks gender: F age at baseline: 5.3m motor status (52 weeks treatment): Walking change in glycogen content (52 weeks treatment): Decreased response: Positive Clinical Outcome
GSM947506
GPL570
Quadriceps_Pompe_7_12wks Quadriceps muscle, Pompe patient, 12 weeks rhGAA treatment tissue: Quadriceps muscle patient: P.q.7 diagnosis: Pompe treatment: rhGAA treatment time (rhgaa): 12 Weeks gender: F age at baseline: 5.3m motor status (52 weeks treatment): Walking change in glycogen content (52 weeks treatment): Decreased response: Positive Clinical Outcome
GSM947507
GPL570
Quadriceps_Pompe_7_52wks Quadriceps muscle, Pompe patient, 52 weeks rhGAA treatment tissue: Quadriceps muscle patient: P.q.7 diagnosis: Pompe treatment: rhGAA treatment time (rhgaa): 52 Weeks gender: F age at baseline: 5.3m motor status (52 weeks treatment): Walking change in glycogen content (52 weeks treatment): Decreased response: Positive Clinical Outcome
GSM947508
GPL570
Quadriceps_Pompe_8_00wks Quadriceps muscle, Pompe patient, 0 weeks rhGAA treatment tissue: Quadriceps muscle patient: P.q.8 diagnosis: Pompe treatment: rhGAA treatment time (rhgaa): 00 Weeks gender: M age at baseline: 6.4m motor status (52 weeks treatment): Standing change in glycogen content (52 weeks treatment): Decreased response: Positive Clinical Outcome
GSM947509
GPL570
Quadriceps_Pompe_8_12wks Quadriceps muscle, Pompe patient, 12 weeks rhGAA treatment tissue: Quadriceps muscle patient: P.q.8 diagnosis: Pompe treatment: rhGAA treatment time (rhgaa): 12 Weeks gender: M age at baseline: 6.4m motor status (52 weeks treatment): Standing change in glycogen content (52 weeks treatment): Decreased response: Positive Clinical Outcome
GSM947510
GPL570
Quadriceps_Pompe_8_52wks Quadriceps muscle, Pompe patient, 52 weeks rhGAA treatment tissue: Quadriceps muscle patient: P.q.8 diagnosis: Pompe treatment: rhGAA treatment time (rhgaa): 52 Weeks gender: M age at baseline: 6.4m motor status (52 weeks treatment): Standing change in glycogen content (52 weeks treatment): Decreased response: Positive Clinical Outcome
GSM947511
GPL570
Quadriceps_Pompe_9_00wks Quadriceps muscle, Pompe patient, 0 weeks rhGAA treatment tissue: Quadriceps muscle patient: P.q.9 diagnosis: Pompe treatment: rhGAA treatment time (rhgaa): 00 Weeks gender: F age at baseline: 1.2m motor status (52 weeks treatment): Walking change in glycogen content (52 weeks treatment): Decreased response: Positive Clinical Outcome
GSM947512
GPL570
Quadriceps_Pompe_9_12wks Quadriceps muscle, Pompe patient, 12 weeks rhGAA treatment tissue: Quadriceps muscle patient: P.q.9 diagnosis: Pompe treatment: rhGAA treatment time (rhgaa): 12 Weeks gender: F age at baseline: 1.2m motor status (52 weeks treatment): Walking change in glycogen content (52 weeks treatment): Decreased response: Positive Clinical Outcome
GSM947513
GPL570
Quadriceps_Pompe_9_52wks Quadriceps muscle, Pompe patient, 52 weeks rhGAA treatment tissue: Quadriceps muscle patient: P.q.9 diagnosis: Pompe treatment: rhGAA treatment time (rhgaa): 52 Weeks gender: F age at baseline: 1.2m motor status (52 weeks treatment): Walking change in glycogen content (52 weeks treatment): Decreased response: Positive Clinical Outcome
GSM947514
GPL570
Quadriceps_Pompe_10_00wks Quadriceps muscle, Pompe patient, 0 weeks rhGAA treatment tissue: Quadriceps muscle patient: P.q.10 diagnosis: Pompe treatment: rhGAA treatment time (rhgaa): 00 Weeks gender: M age at baseline: 6.9m motor status (52 weeks treatment): Walking change in glycogen content (52 weeks treatment): Decreased response: Positive Clinical Outcome
GSM947515
GPL570
Quadriceps_Pompe_10_12wks Quadriceps muscle, Pompe patient, 12 weeks rhGAA treatment tissue: Quadriceps muscle patient: P.q.10 diagnosis: Pompe treatment: rhGAA treatment time (rhgaa): 12 Weeks gender: M age at baseline: 6.9m motor status (52 weeks treatment): Walking change in glycogen content (52 weeks treatment): Decreased response: Positive Clinical Outcome
GSM947516
GPL570
Quadriceps_Pompe_10_52wks Quadriceps muscle, Pompe patient, 52 weeks rhGAA treatment tissue: Quadriceps muscle patient: P.q.10 diagnosis: Pompe treatment: rhGAA treatment time (rhgaa): 52 Weeks gender: M age at baseline: 6.9m motor status (52 weeks treatment): Walking change in glycogen content (52 weeks treatment): Decreased response: Positive Clinical Outcome
GSM947517
GPL570
Quadriceps_Pompe_11_00wks Quadriceps muscle, Pompe patient, 0 weeks rhGAA treatment tissue: Quadriceps muscle patient: P.q.11 diagnosis: Pompe treatment: rhGAA treatment time (rhgaa): 00 Weeks gender: F age at baseline: 2.1m motor status (52 weeks treatment): No gains change in glycogen content (52 weeks treatment): Stable response: Poor Clinical Outcome
GSM947518
GPL570
Quadriceps_Pompe_11_12wks Quadriceps muscle, Pompe patient, 12 weeks rhGAA treatment tissue: Quadriceps muscle patient: P.q.11 diagnosis: Pompe treatment: rhGAA treatment time (rhgaa): 12 Weeks gender: F age at baseline: 2.1m motor status (52 weeks treatment): No gains change in glycogen content (52 weeks treatment): Stable response: Poor Clinical Outcome
 
 
Make groups for comparisons
(2 groups will be compared at a time)
Select GSMs and click on "Add groups"
Enter the group name here:


Select expression type
Transcripts profile based on;
A. Differential status (Up/Down regulation)
B. Absolute calls (Transcribed/Not-detected)
 
Filter results by number of probes